<ѻý>Trifluridine/Tipiracil Combination Misses Mark in Metastatic Colon Cancerѻý> No improvement in PFS versus standard for older patients ineligible for intensive therapy Dec 21, 2021
<ѻý>Targeted Agent Improves Survival in FLT3-Positive Acute Myeloid Leukemiaѻý> OS, EFS improved versus historical controls with addition of midostaurin to chemotherapy Dec 17, 2021
<ѻý>Another Study Reinforces Chemo-Free Therapy for Newly Diagnosed CLLѻý> Ibrutinib-rituximab extends PFS versus chemoimmunotherapy, especially in unmutated disease Dec 16, 2021
<ѻý>Less Is More: Rituximab Retreatment Tops Maintenance for Follicular Lymphomaѻý> Updated analysis confirms advantages of less aggressive approach to low-burden disease Dec 16, 2021
<ѻý>Virgil Abloh's Cardiac Angiosarcomaѻý> The fashion designer's death due to this rare form of cancer took the world by surprise Dec 15, 2021
<ѻý>Gene Therapy Resolves Severe Pain Events in Sickle Cell Diseaseѻý> LentiGlobin also normalized hemoglobin and reduced hemolysis markers Dec 15, 2021
<ѻý>Can Dasatinib Dose Be Halved in Low-Risk CML?ѻý> Lower dose associated with improved tolerability, similar responses in propensity score analysis Dec 14, 2021
<ѻý>CAR T-Cell Win Streak Stopped by Negative Trial in Aggressive LBCLѻý> Patients, trial design, logistics among possible explanations for lack of EFS benefit Dec 14, 2021
<ѻý>Fitusiran Prophylaxis Cuts Bleeding in Hemophilia A/Bѻý> Monthly infusion vs on-demand bypassing agents effective in patients with or without inhibitors Dec 14, 2021
<ѻý>In the Story of Our Practice, We're Always the Heroѻý> When is it right to challenge our medical colleagues? Dec 14, 2021
<ѻý>R-CHOP Toppled in First-Line DLBCL Trialѻý> Replacing vincristine with polatuzumab vedotin improved PFS, without adding toxicity Dec 14, 2021
<ѻý>Gentler Regimen Leads to High Response Rate in Older Patients With B-Cell ALLѻý> One-year OS rate of 78% with fractionated inotuzumab ozogamicin exceeds 60% historical rate Dec 13, 2021
<ѻý>β-Thalassemia Patients Go Transfusion-Free With Gene Therapyѻý> Treatment with beti-cel is "potentially curative" in this transfusion-dependent group Dec 13, 2021
<ѻý>R2 Maintenance for Elderly MCL Patients Worth the Risk?ѻý> Longer PFS with addition of lenalidomide to rituximab, but also more toxicity Dec 13, 2021
<ѻý>Venetoclax Regimens for 'Fit' CLL Yield High Undetectable MRD Ratesѻý> Combined with obinutuzumab, plus or minus ibrutinib, outperforms chemoimmunotherapy Dec 13, 2021
<ѻý>Trastuzumab ADC Active in HER2-Low, HER2-Undetected Breast Cancerѻý> No clear explanation for responses to HER2-targeted drug in HER2-negative tumors Dec 12, 2021
<ѻý>Neratinib-Based Combo Shows Efficacy in HR+, HER2-Mutant Metastatic Breast Cancerѻý> Objective response rate of 42% in patients previously treated with CDK4/6 inhibitors Dec 12, 2021
<ѻý>Novel Bispecific Antibody Nets Durable Remissions in Follicular Lymphomaѻý> Mosunetuzumab offers "clinically meaningful outcomes" in relapsed/refractory disease Dec 12, 2021
<ѻý>Induction Isatuximab-RVd Combo Boosts MRD Negativity in Multiple Myelomaѻý> Half of newly diagnosed, transplant-eligible patients reached minimal residual disease negativity Dec 12, 2021
<ѻý>CAR T-Cell Therapy Makes Strong Case for Earlier Use in Lymphomaѻý> Large increases in event-free survival with two CAR T-cell products in second line Dec 11, 2021
<ѻý>Upfront IDH1 Inhibitor Triples Survival in Older AMLѻý> Median OS for ivosidenib-azacitidine reached 2 years in patients ineligible for intensive therapy Dec 11, 2021
<ѻý>Case of Parkinson's-Like Symptoms in Myeloma Patient After CAR-T Productѻý> FDA advises monitoring patients after T-cell infusion for signs, symptoms of neurotoxicity Dec 10, 2021
<ѻý>'Watch and Switch' Strategy Extends PFS in HR-Positive Breast Cancerѻý> Progression-free survival doubled with treatment change based on monitoring for resistance marker Dec 10, 2021
<ѻý>CDK7 Inhibitor-Based Combo Promising in CDK4/6-Resistant Breast Cancerѻý> Clinical benefit rate of 36%, plus tumor shrinkage, with samuraciclib plus fulvestrant Dec 10, 2021
<ѻý>Pyrotinib Tops Lapatinib in Metastatic HER2-Positive Breast Cancerѻý> Updated PHOEBE trial results now show an overall survival benefit as well Dec 10, 2021
<ѻý>Ethics Consult: Should Doctor Inform Patient's Family of Diagnosis? MD/JD Weighs Inѻý> You voted, now see the results and an expert's discussion Dec 10, 2021
<ѻý>Benefits of Ovarian Suppression Persist in Premenopausal Breast Cancerѻý> Aromatase inhibitor-ovarian suppression tops tamoxifen strategies at 12-13 years Dec 09, 2021
<ѻý>Highly Mutated Breast Cancer Responds to Immunotherapyѻý> Nivolumab-ipilimumab combination associated with durable response in small study Dec 09, 2021
<ѻý>Ribociclib's OS Benefit in Breast Cancer Seen Regardless of Metastatic Siteѻý> Second analysis shows OS benefit consistent across some intrinsic subtypes as well Dec 09, 2021
<ѻý>No Benefit With Metformin in Early Breast Cancer, Regardless of ER/PR Statusѻý> However, there could be improved outcomes in HER2-positive patients Dec 08, 2021
<ѻý>Small PFS Boost With HDAC Inhibitor for Advanced HR-Positive Breast Cancerѻý> Chinese study contradicts U.S. trial that showed no benefit with entinostat add-on Dec 08, 2021
<ѻý>Black Women Most at Risk for Post-Surgical Lymphedemaѻý> Black women seemed to have triple the odds of swelling after axillary lymph node dissection Dec 08, 2021
<ѻý>TROP2-Directed ADC Promising in Advanced Triple-Negative Breast Cancerѻý> Datopotamab deruxtecan turns in solid phase I results Dec 08, 2021
<ѻý>BRAF Inhibition in Pediatric Ameloblastoma of the Jawѻý> Targeted therapy in 3 boys allowed for conservative surgery to restore jaw to predisease state Dec 07, 2021
<ѻý>Hemostatic Powder on Par for Stopping Acute Upper GI Bleedsѻý> In non-inferiority trial, TC-325 matched standard therapy for nonvariceal lesions Dec 07, 2021
<ѻý>Genomic Profiling Improves Outcomes in Breast Cancerѻý> PFS was better when targeted treatment for genomic alterations was supported by ESCAT criteria Dec 07, 2021
<ѻý>But the Cancer Was 'Indolent'ѻý> Tread carefully when offering patients an optimistic outlook Dec 07, 2021
<ѻý>Novel Endocrine Drug Slows Previously Treated HR-Positive Breast Cancerѻý> Elacestrant led to significant improvement in all patients, ESR1-mutant subgroup Dec 07, 2021
<ѻý>Novel Chemoimmunotherapy Regimen Wows in Pediatric Neuroblastomaѻý> "I've never seen anything like this," researcher says of 3-year event-free survival rate Dec 06, 2021
<ѻý>Bevacizumab Add-On No Help in Progressive EGFR-Mutant Lung Cancerѻý> Single-agent osimertinib prevails in progressive, T790M-positive NSCLC Dec 02, 2021